[go: up one dir, main page]

US20100227830A1 - Use of escin - Google Patents

Use of escin Download PDF

Info

Publication number
US20100227830A1
US20100227830A1 US12/376,419 US37641907A US2010227830A1 US 20100227830 A1 US20100227830 A1 US 20100227830A1 US 37641907 A US37641907 A US 37641907A US 2010227830 A1 US2010227830 A1 US 2010227830A1
Authority
US
United States
Prior art keywords
escin
preparation
allergy
disease
granulocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/376,419
Other languages
English (en)
Inventor
Andreas Grassauer
Eva Prieschl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marinomed Biotech AG
Original Assignee
Marinomed Biotechnologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotechnologie GmbH filed Critical Marinomed Biotechnologie GmbH
Assigned to MARINOMED BIOTECHNOLOGIE GMBH reassignment MARINOMED BIOTECHNOLOGIE GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRASSAUER, ANDREAS, PRIESCHL, EVA
Assigned to MARINOMED BIOTECHNOLOGIE GMBH reassignment MARINOMED BIOTECHNOLOGIE GMBH CORRECTIVE ASSIGNMENT TO CORRECT THE ZIPCODE OF THE ASSIGNEE'S ADDRESS FROM 1220 TO 1210 PREVIOUSLY RECORDED ON REEL 022372 FRAME 0189. ASSIGNOR(S) HEREBY CONFIRMS THE EXCLUSIVE RIGHT, TITLE AND INTEREST TO SAID INVENTION IN THE UNITED STATES AND THE LETTERS PATENT APPLICATION. Assignors: GRASSAUER, ANDREAS, PRIESCHL, EVA
Publication of US20100227830A1 publication Critical patent/US20100227830A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • the present invention relates to the field of immunology.
  • An allergy can refer to several kinds of unwanted immune reactions including Type I and Type III hypersensitivities.
  • Leukocytes consist of different cell types that all origin from stem cells in the bone marrow. They are further subdivided into lymphocytes (T-cells, B-cells, natural killer cells), myeloid cells (monocytes, macrophages) and granulocytes (eosinophils, neutrophils, and basophils).
  • Mast cells are closely related to basophils and are often regarded as the tissue residing type of a granulocyte.
  • Granulocytes are defined as eosinophils, neutrophils, basophils, and mast cells.
  • Granulocytes are part of the innate immune response, an unspecific reaction towards pathogens, such as bacteria. This is also reflected by the fact that lipopolysacharide (LPS, component of bacterial cell wall) activation of granulocytes results in a pronounced release of cytokines, such as tumour necrosis factor alpha (TNF-alpha).
  • cytokines such as tumour necrosis factor alpha (TNF-alpha).
  • Activation of granulocytes with either IgE- (type I allergy) or IgG complexes (type III allergy) results in a strong and fast reaction against otherwise innocuous agents (pollen, food, reactions against own structures and tissues such in autoimmune diseases).
  • Mast cells and basophils are the cellular basis for type I allergies (IgE-mediated allergies via the Fc ⁇ RI), neutrophils are involved in type III allergies (immune complex mediated reactions, via the Fc ⁇ RIII) including autoimmune diseases such as psoriasis, arthritis, immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE), and contributes to other autoimmune diseases such as rheumatoid arthritis (RA), type I diabetes and multiple sclerosis. Allergies of both types can result in symptoms as benign as a runny nose, to severe chronic diseases and also to life-threatening anaphylactic shock or septic shock.
  • ITP immune thrombocytopenia
  • AHA autoimmune hemolytic anemia
  • SLE systemic lupus erythematosus
  • RA rheumatoid arthritis
  • Allergies of both types can result in symptoms as benign as a run
  • Type I allergies are commonly treated by corticosteroids (cortisone), anti-histamines, ephinephrine, theophylline or mast cell stabilizers. These compounds block the action of allergic mediators, preventing activation of cells and degranulation processes. These drugs help alleviate the symptoms of allergy but play little role in chronic alleviation of the disorder. All of these therapeutical classes have quite substantial side-effects especially after long-term use. Allergies have an increasing incidence in the western hemisphere with about 20% of the population being affected now. A review and recommendation for treatment of allergic rhinitis has been published by the British National Prescribing Center: MeReC Bulletin Volume 9, Number 3, 1998.
  • Another treatment form of allergies involves the intravenous injection of monoclonal anti-IgE antibodies.
  • Hyposensitization is a form of immunotherapy where the patient is gradually vaccinated against progressively larger doses of the allergen in question. This can either reduce the severity or eliminate hypersensitivity altogether. It relies on the progressive skewing of IgG production, as opposed to the excessive IgE production seen in hypersensitivity type I cases.
  • Allergic diseases type III are commonly treated by steroids, non-steroid anti-inflammatory drugs, methotrexate, and TNF-alpha blocker (receptor analogs or antibodies).
  • Some autoimmune diseases such as psoriasis or blistering diseases are further complicated by secondary infections of the skin.
  • secondary infections that are the result of chronic disorder such as psoriasis are often left untreated.
  • the inflammatory process is worsened and the disease progresses.
  • there is still a strong medical need as many of these substances are not suited for a chronic application or the treatment is too expensive for broad use (biological substances).
  • Psoriasis or rheumatoid arthritis belong to the most common autoimmune diseases with 1-2% of the population being affected.
  • Sirtori discloses an anti-inflammatory effect of aescin which is effected by the reduction of vascular permeability which can reduce the density of leucocytes in affected tissue.
  • Dattner (Dermatologic Therapy 16 (2003): 106-113) discusses horse chestnuts in the field of herbal medicine with an anti-inflammatory and vasoprotective effect. An elastase-inhibitory activity is attributed to escin.
  • a goal of the present invention is to provide further medications, which are effective against diverse immunological diseases that are based on a hyper-response of granulocytes.
  • the present invention provides the use of escin for the manufacture of a pharmaceutical preparation (or a medicament) for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.
  • Leukocytes such as granulocytes play a role in almost all diseases as the body's defense system. Some symptoms of any disease may be related to the direct effector functions of the granulocytes.
  • the term “diseases caused or mediated by granulocytes” is to be understood in the context of the origin of the disease and not only the symptoms of the disease.
  • the diseases to be treated by the pharmaceutical preparation are therefore related to an aberrant or excessive function of granulocytes.
  • the present invention relates to the use of escin for the manufacture of pharmaceutical preparation for the treatment of a disease, wherein the origin of the disease is mediated or caused by activated granulocytes.
  • the granulocytes are hyperactivated. This excessive activation can lead to severe systemic adverse effects like shock syndromes, e.g. allergic shock.
  • the granulocytes, as defined herein, are preferably independently selected from any of eosinophils, neutrophils, basophils and mast cells.
  • the present invention discloses the treatment of a type I or type III allergy, autoimmune diseases or septic shock with a pharmaceutical preparation comprising escin.
  • Escin also called aescin
  • Escin is a triterpene saponin mixture extracted from the seed of chestnut. It is a component of several pharmaceuticals on the market (in Austria: Reparil from Madaus, Opino from Wabosan, Venosin from Astellas and several more). Often the products contain additional pharmaceutically active compounds such as diethylammoniumsalicylic acid, Buphenin and essential oils. Its primary indication is venous insufficiency based on the inhibitory potential of escin on lysosomal proteins and subsequently the reduced permeability of capillaries.
  • HCE horse-chestnut extracts
  • HCSE horse-chestnut seeds extracts
  • Escin is also known as an anti-inflammatory substance, but mainly due to its inhibition of edema. An inhibition of an inflammatory response at cellular level has not been described so far.
  • a detailed review of the use of escin and horse chestnut extracts can be found in: Tiffany at al., Journal of Herbal Pharmacotherapy, Vol. 2 (1) 2002:71-85.
  • the antioedematous mechanism of ⁇ -escin is still unknown, specially at the molecular level. Besides some speculations about the mechanism of action of this molecule exists, clearly further research is needed.
  • NF- ⁇ B nuclear factor-KB
  • TNF-alpha tumor necrosis factor- ⁇
  • escin has proinflammatory effects.
  • it is used as adjuvant in several pharmaceutical preparations (U.S. Pat. No. 7,049,063, U.S. Pat. No. 7,033,827, U.S. Pat. No. 6,943,236, U.S. Pat. No. 6,894,146, U.S. Pat. No. 6,858,204, U.S. Pat. No. 6,800,746, U.S. Pat. No. 6,759,515, U.S. Pat. No. 6,630,305, U.S. Pat. No. 6,509,448, U.S. Pat. No. 6,504,010).
  • An adjuvant is an agent, which, while not having any specific antigenic effect in itself, may stimulate the immune system, increasing the response to a vaccine.
  • escin has in certain conditions also immunostimmulatory uses.
  • an allergy can be treated with escin at a level prior to the stimulation of the immune system.
  • IgE/antigen complexes would provoke TNF-alpha release.
  • mast cell activation and TNF-alpha release was also inhibited by escin in mast cells which do not rely on the NF- ⁇ B pathway. The treatment with escin results in a selective anti-allergic effect of a different pathway.
  • escin can successfully be used in the treatment of allergic diseases and more broadly as inhibitor of activated granulocytes exemplified by an LPS induced shock reaction.
  • Escin is for example able to reduce the allergic reaction followed by a stimulus of a complex of Immunoglobulin E (IgE) and the corresponding antigen in vitro.
  • Escin inhibits dose-dependently an LPS-mediated release of TNF-alpha in primary human blood.
  • escin dramatically reduces the effect of an immunological shock in an in vivo model and was effectively used to treat an ongoing allergic reaction in a patient suffering from uticaria pigmentosa.
  • Lymphocytes as exemplified by the human T-cell line Jurkat or myeloid cells as exemplified by the murine monocytic cell line DC18 were not inhibited by escin after stimulation (release of either IL-2 or TNF-alpha respectively). Contrary to previous assumptions (Xiao et al., supra) of molecular targets of escin the anti-allergic effect of escin is independent of NF- ⁇ B. According to the present invention it was found that escin had still an anti-allergic effect in NF- ⁇ B pathway independent mast cells (CFTL12).
  • the pharmaceutical preparation to be used according to the present invention contains escin as the only granulocyte-inhibiting component, preferably as the only pharmaceutically active agent.
  • the allergic disease is a chronic disease or an unwanted hyper-reaction of granulocytes.
  • Escin containing products have been on the market since many years and have an excellent safety profile. Therefore the use of escin either alone or in combination with other drugs is an attractive option for chronic patients.
  • the allergic disease is a type I or III allergy, preferably mediated by myeloid cells or granulocytes, or an unwanted reaction of granulocytes.
  • the medicament is preferably used to treat an allergic disease selected from any one of allergic rhinitis, Urticaria pigmentosa, atopic dermatitis, allergic asthma, food allergy, allergic conjunctivitis, allergy of the intestinal or uro-genital tract and an allergy of the ears.
  • the medicament is preferably used to treat type III allergic diseases or other autoimmune disorders, such as psoriasis, arthritis, immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type I diabetes and multiple sclerosis.
  • the medicament is preferably used to treat skin diseases with an enhanced activation of granulocytes also including diseases complicated by secondary bacterial infections.
  • the pharmaceutical preparation is in form of a preparation for topical or mucosal use, preferably skin lotions, cremes, powders, sprays or gargle solutions.
  • the escin preparation is especially suitable for topical application to treat skin or mucosal symptoms of the granulocyte mediated disease such as inflammation. But also systemic, e.g. parenteral or oral (also for specific mucosal treatment), is possible.
  • the preparation is in form for oral intake, preferably in form of pastilles, tablets, gums, lozenges, powders or drinking solutions.
  • Systemic distribution of escin is especially preferred in cases with systemic granulocyte activation such as an anaphylactic shock or septic shock.
  • the preparation may also comprise pharmaceutical carriers, excipients, preferably polymeric excipients, or additives.
  • carrier refers to a diluent, e.g. water, saline, excipient, or vehicle with which the composition can be administered.
  • the carriers or additives in the pharmaceutical composition may comprise SiO 2 , TiO 2 , a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatine, starch, lactose or lactose monohydrate, alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin.
  • the preparation comprises buffers or pH adjusting agents, e.g.
  • Escin in the form of a pharmaceutically acceptable salt for example sodium salt may also be used.
  • Other pharmaceutically acceptable salts include, among others, potassium, lithium and ammonium salts.
  • Preferred excipients are polymers, especially cellulose and cellulose derivatives.
  • escin is in doses between 0.01 mg per kg of a patient and 500 mg/kg, preferably between 0.1 mg/kg and 100 mg/kg, most preferred between 1 mg/kg and 40 mg/kg.
  • the present invention also provides the use of the pharmaceutical preparations.
  • the administration of the preparation is not limited to administrations at the same time of an allergic reaction but can also be used before or after the reaction, e.g. for prophylactic treatment, i.e. a treatment before an expected exposure to an allergen to reduce the force of the reaction.
  • FIG. 1 Inhibition of TNF-alpha production of LPS-stimulated human blood cells.
  • Human blood was incubated with the indicated concentrations of escin.
  • Cells were stimulated with 100 ng/ml LPS (Sigma) and the TNF-alpha in the supernatant was determined with a commercial ELISA Kit (Bender-Med-Systems) after 18 hours of stimulus.
  • the x-axis gives the concentrations of escin in ⁇ g/ml
  • the y-axis gives the concentration of TNF-alpha in pg/ml.
  • FIG. 2 Inhibition of TNF-alpha production from IgE/antigen stimulated mast cells.
  • CFTL12 Mast cells were incubated with concentrations ranging from 3.1 ⁇ M to 0.03 ⁇ M ⁇ -escin and 0.3 ⁇ M Dexamethasone respectively. 60 minutes later cells were stimulated with an IgE/antigen complex. Cells were incubated at 37° C. for 6 hours and TNF-alpha in the supernatant was determined by a commercial mouse TNF-alpha ELISA (Bender-Med-Systems). Error bars indicate the standard deviation between 4 independent wells.
  • FIG. 4 Symptoms score of a patient with uticaria pigmentosa: A 49 year old patient with uticaria pigmentosa was treated on affected areas of both legs with a gel containing 1.5% escin. The score of symptoms for each area was recorded and documented by digital photography. Treatment for the left leg started at point 0. Diamonds indicate the score of the left leg. Due to the surprising fast response of the left leg the treatment of the right leg was initiated after one hour (quarters). A small area of the skin was left untreated (triangles). X-axis gives the time-points after treatment initiation in hours;
  • Escin is Active against LPS Induced TNF-Alpha Release
  • TNF-alpha is a mediator that is central in an inflammatory process as observed during infections, and autoimmune diseases. It is released by white blood cells, endothelium and several other tissues in the course of damage, e.g. by infection but also during an allergic reaction. Its release is stimulated by several other mediators, such as interleukin 1 and bacterial endotoxin. Cell based assays using human primary blood cells stimulated with lipopolysaccharide demonstrated that escin dose-dependently inhibits TNF-alpha release ( FIG. 1 ).
  • Application of escin reduces the release of this mediator in a dose dependent manner.
  • TNF-induction in mice administration of lipopolysaccharide is a well established model for fast immunological reactions and a model for septic shock. As shown in FIG. 3 the treatment of mice with 15 mg/kg of escin reduces the TNF-alpha level to 30%.
  • a patient diagnosed with uticaria pigmentosa a disease that is characterized by unspecific allergic reactions caused by an overreaction of mast cells.
  • the 49 year old female patient had a history of allergic reactions mainly of the skin and in some cases systemic manifestations that were treated with antihistamines and corticosteroids.
  • Prior treatment a strong allergic reaction was ongoing on the skin of large areas of both legs and hands. The patient reported itching and pain of the skin. Clearly the inflammation of the skin was visible.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
US12/376,419 2006-08-04 2007-08-03 Use of escin Abandoned US20100227830A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06450109A EP1884245A1 (en) 2006-08-04 2006-08-04 Use of Escin
EP06450109.1 2006-08-04
PCT/EP2007/006870 WO2008015007A2 (en) 2006-08-04 2007-08-03 Use of escin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/006870 A-371-Of-International WO2008015007A2 (en) 2006-08-04 2007-08-03 Use of escin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/281,635 Continuation US9993512B2 (en) 2006-08-04 2016-09-30 Use of escin

Publications (1)

Publication Number Publication Date
US20100227830A1 true US20100227830A1 (en) 2010-09-09

Family

ID=37969918

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/376,419 Abandoned US20100227830A1 (en) 2006-08-04 2007-08-03 Use of escin
US15/281,635 Active US9993512B2 (en) 2006-08-04 2016-09-30 Use of escin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/281,635 Active US9993512B2 (en) 2006-08-04 2016-09-30 Use of escin

Country Status (21)

Country Link
US (2) US20100227830A1 (es)
EP (2) EP1884245A1 (es)
JP (1) JP5345933B2 (es)
KR (1) KR20090034946A (es)
CN (1) CN101500582B (es)
AU (1) AU2007280625B2 (es)
BR (1) BRPI0715070B8 (es)
CA (1) CA2658279C (es)
DK (1) DK2046345T3 (es)
EA (1) EA015404B1 (es)
ES (1) ES2531516T3 (es)
HR (1) HRP20141243T1 (es)
IL (1) IL196606A (es)
MX (1) MX2009000991A (es)
NZ (1) NZ574249A (es)
PL (1) PL2046345T3 (es)
PT (1) PT2046345E (es)
SI (1) SI2046345T1 (es)
UA (1) UA94954C2 (es)
WO (1) WO2008015007A2 (es)
ZA (1) ZA200900372B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463155B2 (en) 2013-03-15 2016-10-11 Mary Kay Inc. Cosmetic compositions and uses thereof
US9801900B2 (en) 2013-11-22 2017-10-31 Mary Kay Inc. Compositions for sensitive skin

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2445870T3 (es) * 2008-07-01 2014-03-05 Marinomed Biotechnologie Gmbh Biopolímeros antialérgicos marinos
EP2186523A1 (en) * 2008-11-18 2010-05-19 Marinomed Biotechnologie GmbH Use of escin for treatment of Type IV hypersensitivity reaction
ES2346844B1 (es) * 2010-03-17 2011-08-09 Ricardo Lombardero Calzon Crema para quemaduras.
WO2012101618A1 (en) 2011-01-28 2012-08-02 Barcelcom Têxteis S.A. Compression stockings and tubes with bioactive agents for the treatment of venous insufficiency and varicose veins
CN104147055A (zh) * 2014-07-08 2014-11-19 武汉爱民制药有限公司 赖氨酸七叶皂苷及其盐在制备治疗i型超敏反应药物中的用途
US20180154777A1 (en) * 2016-12-02 2018-06-07 Faraday&Future Inc. Braking torque blending system and method for automatic emergency braking
IT202100014495A1 (it) * 2021-06-08 2022-12-08 Neilos S R L "Composizione per l’uso nella prevenzione e/o nel trattamento di patologie osteoarticolari"

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3402259A1 (de) * 1984-01-24 1985-08-01 Stephan Dr.med. 3000 Hannover Regöczy Therapeutisch wirksames gemisch, insbesondere zur behandlung von infektionskrankheiten im hals-, nasen- ohrenbereich, stimmbandentzuendungen, schwerer heiserkeit und trombophlebitis
US6504010B1 (en) * 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) * 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6630305B1 (en) * 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) * 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6858204B2 (en) * 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6894146B1 (en) * 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) * 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) * 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US7049063B2 (en) * 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1676561U (de) 1954-03-27 1954-05-20 Lutz Kg Maschf Eugen Vorrichtung zum fraesen von nuten u. dgl. mittels einer motor-oberfraese.
DE3445324A1 (de) * 1984-12-12 1986-06-12 Klinge Pharma GmbH, 8000 München Arzneimittelkombination mit synergistischer wirkung
IT1252866B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3402259A1 (de) * 1984-01-24 1985-08-01 Stephan Dr.med. 3000 Hannover Regöczy Therapeutisch wirksames gemisch, insbesondere zur behandlung von infektionskrankheiten im hals-, nasen- ohrenbereich, stimmbandentzuendungen, schwerer heiserkeit und trombophlebitis
US6759515B1 (en) * 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) * 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) * 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) * 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US7049063B2 (en) * 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US6504010B1 (en) * 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) * 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) * 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6630305B1 (en) * 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Regoczy, Stephan; machine translation of DE 3402259 obtained 10 September 2012 *
Van Cauwenberge, P. et al., Allergy, "Consensus statement on the treatment of allergic rhinitis", 2000, vol. 55, pp.116-134 *
WebMD, "Decongestants for Sinusitis"; also available at http://www.webmd.com/a-to-z-guides/decongestants-for-sinusitis; last updated 03 August 2010 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463155B2 (en) 2013-03-15 2016-10-11 Mary Kay Inc. Cosmetic compositions and uses thereof
US10299994B2 (en) 2013-03-15 2019-05-28 Mary Kay Inc. Cosmetic compositions and uses thereof
US11135139B2 (en) 2013-03-15 2021-10-05 Belaj Innovations Llc Cosmetic compositions and uses thereof
US11723845B2 (en) 2013-03-15 2023-08-15 Mary Kay Inc. Cosmetic compositions and uses thereof
US9801900B2 (en) 2013-11-22 2017-10-31 Mary Kay Inc. Compositions for sensitive skin
US10245282B2 (en) 2013-11-22 2019-04-02 Mary Kay Inc. Compositions for sensitive skin
US10736837B2 (en) 2013-11-22 2020-08-11 Mary Kay Inc. Compositions for sensitive skin
US11559480B2 (en) 2013-11-22 2023-01-24 Mary Kay Inc. Compositions for sensitive skin
US11865204B2 (en) 2013-11-22 2024-01-09 Mary Kay Inc. Compositions for sensitive skin
US12233154B2 (en) 2013-11-22 2025-02-25 Mary Kay Inc Compositions for sensitive skin

Also Published As

Publication number Publication date
MX2009000991A (es) 2009-04-16
WO2008015007A3 (en) 2008-04-03
AU2007280625B2 (en) 2012-05-17
ES2531516T3 (es) 2015-03-16
IL196606A0 (en) 2009-11-18
HRP20141243T1 (hr) 2015-02-13
AU2007280625A1 (en) 2008-02-07
PT2046345E (pt) 2014-12-26
WO2008015007A2 (en) 2008-02-07
NZ574249A (en) 2011-04-29
EP2046345A2 (en) 2009-04-15
BRPI0715070B1 (pt) 2021-04-13
DK2046345T3 (en) 2015-01-26
CN101500582A (zh) 2009-08-05
KR20090034946A (ko) 2009-04-08
PL2046345T3 (pl) 2015-05-29
CA2658279A1 (en) 2008-02-07
CN101500582B (zh) 2011-08-24
ZA200900372B (en) 2009-12-30
EP2046345B1 (en) 2014-12-10
SI2046345T1 (sl) 2015-03-31
BRPI0715070B8 (pt) 2021-05-25
EP1884245A1 (en) 2008-02-06
JP5345933B2 (ja) 2013-11-20
IL196606A (en) 2015-08-31
EA015404B1 (ru) 2011-08-30
US9993512B2 (en) 2018-06-12
EA200900261A1 (ru) 2009-06-30
UA94954C2 (uk) 2011-06-25
BRPI0715070A2 (pt) 2013-06-25
US20170014465A1 (en) 2017-01-19
JP2009545623A (ja) 2009-12-24
CA2658279C (en) 2014-10-28

Similar Documents

Publication Publication Date Title
US9993512B2 (en) Use of escin
EP2969010B1 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
AU2009266076B2 (en) Antiallergic marine biopolymers
CN113209154B (zh) 鸡骨香提取物在制备预防和/或治疗溃疡性结肠炎药物中的应用
JP2005514414A5 (es)
KR20040050622A (ko) 아토피성 피부염의 예방 또는 치료용 조성물 및 그 제조방법
TWI776234B (zh) 藥學組合物及其於治療肌少症之用途
US20110224160A1 (en) Use of Escin for Treatment of Type IV Hypersensitivity Reaction
CN1852723A (zh) 天竺葵种提取物的用途
Shingadiya et al. Ayurvedic management of chronic vitiligo (Shvitra): A case study
CN101400255B (zh) 用于治疗细菌、病毒、真菌疾病、炎症以及疼痛的组合物
KR100591164B1 (ko) 염증성 질환의 예방 또는 치료용 생약 추출물 및 그제조방법
KR101308666B1 (ko) 참치 안구 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
CN113230255A (zh) 阿帕替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用
KR20140049158A (ko) 봉독을 포함하는 피부 소양증 개선용 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: MARINOMED BIOTECHNOLOGIE GMBH, AUSTRIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRASSAUER, ANDREAS;PRIESCHL, EVA;REEL/FRAME:022372/0189

Effective date: 20090119

AS Assignment

Owner name: MARINOMED BIOTECHNOLOGIE GMBH, AUSTRIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ZIPCODE OF THE ASSIGNEE'S ADDRESS FROM 1220 TO 1210 PREVIOUSLY RECORDED ON REEL 022372 FRAME 0189. ASSIGNOR(S) HEREBY CONFIRMS THE EXCLUSIVE RIGHT, TITLE AND INTEREST TO SAID INVENTION IN THE UNITED STATES AND THE LETTERS PATENT APPLICATION;ASSIGNORS:GRASSAUER, ANDREAS;PRIESCHL, EVA;REEL/FRAME:022477/0161

Effective date: 20090119

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION